← Back to Search

Radiation

Post-SABR Biopsy for Lung Cancer

N/A
Waitlist Available
Led By Khinh Ranh Voong, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adequate normal organ and marrow function
Patient with tumor amenable to SABR treatment as determined by a radiation oncologist
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to up to 7 days after sabr treatment
Awards & highlights

Study Summary

This trial will compare how well two different types of biopsies, taken before and after a treatment for lung cancer, can identify which tumors the treatment has worked on.

Who is the study for?
Adults over 18 with Stage I non-small cell lung cancer that can be treated with SABR and biopsied are eligible. They must have normal organ function, not be pregnant, and agree to follow the study protocol. Excluded are those on steroids close to radiation treatment, prior thoracic radiation in the same area, or current chemotherapy/immunotherapy.Check my eligibility
What is being tested?
The trial is testing how stage I NSCLC tumors respond immunologically to a type of targeted radiotherapy called SABR by examining T-cell changes before and after treatment using advanced genomic analysis techniques.See study design
What are the potential side effects?
While specific side effects aren't listed for this observational study, common ones from SABR may include fatigue, skin reactions at the treatment site, chest pain, shortness of breath, and cough.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My organs and bone marrow are functioning well.
Select...
My tumor can be treated with a specific type of targeted radiation therapy.
Select...
I am willing and able to follow the study's treatment plan and attend all visits.
Select...
I am older than 18 years.
Select...
My lung cancer was confirmed through initial biopsies.
Select...
I have enough biopsy samples for further testing.
Select...
My lung cancer is in the early stage (Stage I).
Select...
I am post-menopausal or not currently pregnant.
Select...
My tumor can be easily reached for a biopsy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to up to 7 days after sabr treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to up to 7 days after sabr treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Induced T-cell receptor (TCR) profile changes in tumor after stereotactic ablative radiotherapy (SABR) as determined by number of times increase in amount of identified TCR CDR3 regions.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stage I NSCLC with SABR TherapyExperimental Treatment1 Intervention
Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
554 Previous Clinical Trials
32,904 Total Patients Enrolled
Khinh Ranh Voong, MDPrincipal InvestigatorJohns Hopkins University

Media Library

SABR (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT03603002 — N/A
Non-Small Cell Lung Cancer Research Study Groups: Stage I NSCLC with SABR Therapy
Non-Small Cell Lung Cancer Clinical Trial 2023: SABR Highlights & Side Effects. Trial Name: NCT03603002 — N/A
SABR (Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03603002 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to join this experiment?

"According to the data hosted on clinicaltrials.gov, this experiment is actively seeking participants. It was initially posted in October 2018 and has been modifyied most recently in September 2022."

Answered by AI

May I be part of this research experiment?

"This medical study seeks 10 volunteers between 18-100 years of age who possess a malignancy in their lungs. The applicants must be willing and capable to comply with all aspects of the clinical trial including subsequent treatments and evaluations, have an accessible tumor for biopsy, and demonstrate that their tumour is suitable for SABR therapy as declared by a radiation oncologist."

Answered by AI

Is there an age restriction for enrolment into this experiment?

"According to the specifications of this clinical trial, only individuals aged 18-100 can join. This is distinct from 42 studies that accept patients younger than 18 and 1904 trials open for enrolment by those over 65 years old."

Answered by AI

What is the total enrolment number for this research endeavor?

"Affirmative. Clinicaltrials.gov conveys that this medical investigation, which was initially uploaded on October 16th 2018, is actively recruiting patients. Approximately 10 volunteers need to be recruited from a single healthcare facility."

Answered by AI
~1 spots leftby Mar 2025